Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Leukemia 8Leukemia, Myeloid, Chronic-Phase 6Blast Crisis 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Sarcoma 4Melanoma 4Gastrointestinal Stromal Tumors 4Leukemia, Myeloid, Accelerated Phase 3Sarcoma, Synovial 2Oligodendroglioma 2Leukemia, Myeloid, Acute 2Glioma 2Colorectal Neoplasms 2Central Nervous System Neoplasms 2Brain Neoplasms 2Astrocytoma 2Uterine Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Sarcoma, Endometrial Stromal 1Sarcoma, Alveolar Soft Part 1Rhabdomyosarcoma 1Refractory Desmoplastic Small Round Cell Tumors 1Prostatic Neoplasms 1Primary Myelofibrosis 1Piebaldism 1Ovarian Neoplasms 1Neurofibrosarcoma 1Neurofibromatoses 1

Interventions

Irinotecan 35,10-methylenetetrahydrofolic acid 2tislelizumab 1spartalizumab 1repotrectinib 1pralsetinib 1palbociclib 1encorafenib 1Pemetrexed 1Levoleucovorin 1Leucovorin 1KRN-330 1Immune Checkpoint Inhibitors 1Imatinib Mesylate 1Gemcitabine 1Flucytosine 1Everolimus 1Cisplatin 1Cetuximab 1Capecitabine 1Ascorbic Acid 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Digestive System Neoplasms × Imatinib Mesylate × Clear all
NCT01275222 2021-06-25

Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors

Novartis

Phase 1/2 Completed
117 enrolled 18 charts
GastrointestinalSarcoma

Digestive System Neoplasms, Sarcoma, Stomach Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡